Abstract:What's new? The COVID‐19 pandemic significantly affected the care of lung cancer patients. In particular, fear of infection and overlap of respiratory symptoms complicated lung cancer diagnosis and treatment. Here, the authors investigated mortality risk among patients newly diagnosed with lung cancer specifically during the COVID‐19 pandemic. Mortality risk was found to be 1.2 times higher among newly diagnosed patients, compared to patients diagnosed before the pandemic. Half the increase in mortality rate could be attributed to diagnosis at older age, decreased cancer screening, and a lack of tumor‐directed treatment. Cancer stage and histological confirmation had no impact on increased mortality risk. COVID‐19 pandemic has had a substantial effect on healthcare systems worldwide, including the care of patients with lung cancer. The impact of healthcare disruptions and behavioral changes on lung cancer mortality is unclear. Patients newly diagnosed with lung cancer during the pandemic period 2020–2021 were compared with those diagnosed in the pre‐pandemic 2018–2019. The primary outcome was all‐cause mortality within 1 year. Cox proportional hazards regression analyses were conducted to estimate the changes in mortality between pandemic and pre‐pandemic. Multiple mediation analyses were performed to determine the factors that accounted for the changes in mortality. In total, 5785 patients with lung cancer were included in this study. The overall mortality rate was significantly higher during the pandemic compared with the pre‐pandemic (crude hazard ratio [HR]: 1.19, 95% confidence interval [CI]: 1.05, 1.29). Mediation analyses showed that not receiving tumor‐directed treatment, diagnosis at an older age, and decreased diagnosis through cancer screening significantly accounted for 17.5% (95%CI: 4.2, 30.7), 13.9% (95%CI: 0.8, 27.0), and 12.4% (95%CI: 3.0, 21.8) of the increased mortality, respectively. This study revealed a significant increase in mortality risk in patients with lung cancer who have not received tumor‐directed treatment or cancer screening, despite potential selection bias for follow‐up status. Efforts should be focused on ensuring timely access to healthcare services, optimizing treatment delivery, and addressing the unique challenges faced by patients with lung cancer during the pandemic to mitigate the impact of the pandemic on lung cancer outcomes and provide clinical care to vulnerable populations.

Effects of the COVID-19 pandemic on surgical treatment for thoracic malignant tumor cases in Japan: a national clinical database analysis

Impact of the COVID‐19 pandemic on gastric surgery in Japan: A nationwide study using interrupted time‐series analyses

Impact of SARS-CoV-2 infection on short-term postoperative outcomes after gastroenterological cancer surgery using data from a nationwide database in Japan

Association between the COVID-19 pandemic and short-term outcomes after esophagectomy for esophageal cancer in facilities with and without board-certified esophageal surgeons: a nationwide retrospective cohort study

Analysis of surgical volume and short‐term outcomes for upper gastrointestinal cancer post‐COVID‐19: Evidence from a nationwide Japanese database

Impact of the COVID‐19 pandemic on the number and short‐term outcomes in hepatectomy for hepatocellular carcinoma: Results from the Japanese National Clinical Database, 2018–2021

Effects of the Coronavirus disease 2019 pandemic on mortality in patients with lung cancer: A multiple mediation analysis in Japan

Impact of the COVID‐19 pandemic on short‐term outcomes after pancreaticoduodenectomy for pancreatic cancer: A retrospective study from the Japanese National Clinical Database, 2018–2021

Impact of the COVID-19 pandemic on colorectal cancer surgery in Japan: Clinical Study Group of Osaka University-A multicenter retrospective study

Impact of the novel coronavirus infection on pediatric surgery: an analysis of data from the National Clinical Database

Impact of the coronavirus disease 2019 pandemic on 20 representative surgical procedures in Japan based on the National Clinical Database: annual surveillance of 2021 by the Japan Surgical Society

Investigation of the impact of COVID‐19 on postoperative outcomes using a nationwide Japanese database of patients undergoing laparoscopic distal gastrectomy and low anterior resection for gastric cancer and rectal cancer

Current status of surgery for clinical stage IA lung cancer in Japan: analysis of the national clinical database

Impact of the coronavirus disease 2019 pandemic on the number of colorectal cancer surgeries performed: analysis of a nationwide inpatient database in Japan

Effects of COVID-19 pandemic on hospital visit of head and neck cancer patients

Thoracic surgery in the COVID-19 era: an Italian university hospital experience

Considerations for the Surgical Management of Thoracic Cancers During the COVID-19 Pandemic: Rational Strategies for Thoracic Surgeons

Impact of COVID-19 pandemic on bone and soft tissue sarcoma patients' consultation and diagnosis

The impact of COVID-19 pandemic on head and neck cancer diagnosis and treatment

Impact of COVID-19 on gynecological cancer incidence: a large cohort study in Japan

Trends and current status of general thoracic surgery in Japan revealed by review of nationwide databases